Sandoz – Recall of ranitidine

- On September 23, 2019, the FDA announced a consumer-level recall of several lots of Sandoz's ranitidine capsules because of confirmed contamination with N-Nitrosodimethylamine (NDMA) above levels established by the FDA in batches of Sandoz's ranitidine capsules.

- NDMA is classified as a probable human carcinogen based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

- The recalled ranitidine capsules were distributed nationwide to wholesalers and includes 30 count, 60 count and 500 count bottles in the following lots:

Product Description	NDC#	Lot# (Expiration Date)
Ranitidine 150 mg capsules, 500 count bottle	0781-2855-05	HD1862 (4/30/2020); HP9438 (9/30/20200; HP9439 (9/30/2020); HP9440 (9/30/2020)
Ranitidine 150 mg capsules, 60 count bottle	0781-2855-60	HC9266 (4/30/2020); HD1865 (4/30/2020); HP9441 (9/30/2020); JK7994 (8/31/2021); JK8659 (8/31/2021)
Ranitidine 300 mg capsules, 30 count bottle	0781-2865-31	HD8625 (4/30/2020); HD9275 (4/30/2020); HU2207 (8/31/2020); HX6676 (3/31/2021); HX6677 (3/31/2021)

- Ranitidine is indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable.

- Patients are asked to continue taking their medication and speak to their physician or pharmacist on alternative healthcare treatment options.

- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled ranitidine.

- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.

- Any general questions regarding the recall product should be directed to Sandoz at **1-800-525-8747**.